Indication: For the treatment of pseudomonas aeruginosa lung infections
Pharmacology: Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections.
Mechanism Of Action: Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Drug Category: Anti-bacterial Agents; Aminoglycosides; ATC:J01GB01; ATC:S01AA12
Dosage Forms: Ophthalmic Ointment; POWDER FOR SOLUTION; Solution for oral inhalation; Ophthalmic Solution; Oral Solution; IV Solution
Absorption: Not Available
Interactions:
DrugBank: Interactions for Tobramycin
Interactions for Tobramycin:
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME®, Genentech),
(beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides
demonstrated adverse experience profiles similar to the study population as a whole.
Concurrent and/or sequential use of TOBI with other drugs with neurotoxic or ototoxic potential should be avoided.
Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI
should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
Chemical IUPAC Name: 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol
